trigonellinamide (TRIA-662) / Pharmena - LARVOL DELTA

A Pilot Study to Evaluate the Lipid Effects of TRIA-662 (clinicaltrials.gov) - P2; N=64; Active, not recruiting; Sponsor: Cortria Corporation; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Dyslipidemia